Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

The beauty industry is undergoing a significant transformation, driven by scientific advances, evolving consumer expectations ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Genscript Biotech ( ($HK:1548) ) just unveiled an announcement. Genscript Biotech Corporation held its Annual General Meeting on May 29, 2025, ...

Inc. , (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $86.75, with a ...

The industrial and energy segments saw a strong representation, with Inox Wind, PTC Industries, AstraZeneca Pharma, Inox Wind ...

Thermo Fisher's 2025 headwinds from tariffs and US research funding cuts are real but temporary. Read why TMO stock is a ...

The installation was finalized during Q1 2025 and supports critical pharmaceutical storage and cold chain logistics operations. This deployment represents the continuation of a multi-year relationship ...

With Boster Bio's latest promotion, scientists globally enjoy free access to antibody validation to boost research accuracy.

Healthpeak’s development projects across its life science portfolio should be completed at development yields above the company's weighted average cost of capital and could drive strong internal ...

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...